Live Breaking News & Updates on Blood Culture Identification Panels

Study Highlights Potential Clinical Value of ePlex® Blood Culture ID Panels
Major teaching hospital in Grenoble, France demonstrates that ePlex BCID results could have modified antimicrobial treatment in 45% of patients
CARLSBAD, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, announced today the publication of a manuscript in
Frontiers in Cellular and Infection Microbiology that highlights strong performance and the potential clinical impact of the ePlex Blood Culture Identification (BCID) Panels. The study, “Evaluation of Microbiological Performance and the Potential Clinical Impact of the ePlex
® Blood Culture Identification Panels for the Rapid Diagnosis of Bacteremia and Fungemia,” looked prospectively at the identification of pathogens and antimicrobial resistance genes, as well as retrospectively analyzing clinical outcomes, based on eP ....

Yvan Caspar , Lauren Martin , Grenoble Alpes University Hospital , Exchange Commission , University Practitioner , Bacteriology Laboratory , National Reference Center , Genmark Diagnostics Inc , Study Highlights Potential Clinical Value , Blood Culture , Mark Diagnostics , Infection Microbiology , Plex Blood Culture Identification , Microbiological Performance , Potential Clinical Impact , Blood Culture Identification Panels , Rapid Diagnosis , Plex Blood Culture Identification Panels , Hospital University Practitioner , Grenoble Alpes University , Fungal Pathogen , Utilizing Genmark , True Sample To Answer Solution , Investegate Announcements , Investegate Company Announcements , Genmark Diagnostics ,